Marcaine 0,5 % Adrénaline

Bupivacaine hydrochloride, the active ingredient in Marcaine 0,5 % Adrénaline, is a local anesthetic presented as a 0.5% solution for injection for epidural and infiltration use. It provides regional anesthesia for surgical procedures and pain management in adult patients.

GNH USA supplies Marcaine 0,5 % Adrénaline as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and procurement teams worldwide.

Marcaine 0,5 % Adrénaline, a combination local anesthetic, is used in procedures requiring regional nerve block or infiltration anesthesia.

- Surgical anesthesia: provides local or regional anesthesia for a variety of surgical procedures. - Epidural anesthesia: produces a prolonged epidural block for obstetric or postoperative pain control. - Infiltration anesthesia: delivers targeted anesthesia for minor surgeries or wound repair.

Adverse reactions may occur following administration of Marcaine 0,5 % Adrénaline.

Common Side Effects: - Transient pain at the injection site - Tingling or numbness in the treated area - Mild hypotension due to epinephrine - Bradycardia

Serious or Rare Side Effects: - Cardiac arrhythmias - Seizures - Methemoglobinemia - Allergic reactions, including anaphylaxis

Proper assessment and handling are essential when using this injectable anesthetic.

- Patient assessment: evaluate cardiovascular status before administration. - Dose limitation: avoid exceeding the recommended maximum dose. - Hepatic impairment: use with caution in patients with liver dysfunction. - Intravascular injection: aspirate before injection to prevent systemic exposure. - Monitor for toxicity: observe for signs of central nervous system or cardiac toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Marcaine 0,5 % Adrénaline may interact with several drug classes.

Major Interactions (Avoid): - Beta‑adrenergic blockers: may potentiate epinephrine‑induced hypertension. - Class I antiarrhythmics (e.g., quinidine): increase risk of cardiac toxicity. - MAO inhibitors: may enhance epinephrine effects.

Moderate Interactions (Monitor Closely): - Other local anesthetics: additive neuro‑ and cardiotoxicity. - Calcium channel blockers: may affect cardiac conduction when combined. - General anesthetics: may potentiate central nervous system depression.